Enfiera 100 mg Injection Supplier USA | Pharmaceutical Exporter from India

Enfiera 100 mg Injection: Targeted CD20 Therapy for B-Cell Malignancies and Autoimmune Disorders

Are you seeking a reliable Enfiera 100 mg injection exporter from India? Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced monoclonal antibodies. We maintain a high-authority, cold-chain-compliant supply chain serving the USA, UK, Australia, and South Africa, ensuring that life-saving immunotherapy treatments reach healthcare providers with pharmaceutical-grade integrity and efficient global logistics.

Detailed Product Overview: What is Enfiera 100 mg?

Enfiera 100 mg Injection is a therapeutic monoclonal antibody containing the active pharmaceutical ingredient Rituximab. Manufactured by Biochem Pharmaceutical Industries Ltd. (and distributed via Zydus and other strategic partners), Enfiera is a high-quality biosimilar to the reference product Rituxan.

For international B2B procurement, Enfiera 100 mg provides a clinically validated, cost-effective solution for treating cancers and autoimmune diseases that involve overactive B-lymphocytes. It is supplied as a 100 mg/10 ml concentrate for intravenous infusion.

Primary Therapeutic Indications

Enfiera 100 mg is used globally for:

1. Non-Hodgkin Lymphoma (NHL): Used as a single agent or in combination with chemotherapy for various types of NHL.

2. Chronic Lymphocytic Leukemia (CLL): Combined with chemotherapy for patients with untreated and previously treated CLL.

3. Rheumatoid Arthritis (RA): In combination with methotrexate for adult patients with moderate-to-severe active RA who have had an inadequate response to TNF-inhibitors.

4. Granulomatosis with Polyangiitis (GPA) & Microscopic Polyangiitis (MPA): For the treatment of severe inflammation of the blood vessels.

5. Pemphigus Vulgaris: For adult patients with moderate-to-severe skin blistering disorders.

Mechanism of Action: How Enfiera Works

Enfiera works through a precise immunological mechanism known as B-cell depletion:

• CD20 Targeting: Rituximab specifically binds to the CD20 antigen, a protein found on the surface of both normal and malignant B-lymphocytes.

• Immune-Mediated Destruction: Once bound, Enfiera triggers the patient’s own immune system to attack the B-cells through the following:

  • Antibody-Dependent Cellular Cytotoxicity (ADCC)

  • Complement-Dependent Cytotoxicity (CDC)

  • Apoptosis (Direct Cell Death)

• Sparing Stem Cells: Because CD20 is not expressed on hematopoietic stem cells, the body can eventually repopulate healthy B-cells after the treatment is completed.

Administration and Clinical Safety

• Infusion Protocol: Enfiera must be administered by a healthcare professional as an intravenous infusion. It should never be given as an IV bolus or push.

• Pre-Medication: Patients are typically given an antihistamine and an anti-pyretic (fever-reducer) before the infusion to reduce the risk of infusion-related reactions.

• Storage Requirements: This biological product must be kept in a strict cold chain between 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze.

• Key Safety Monitoring:

  • Infusion Reactions: Monitoring is critical during the first infusion for signs of fever, chills, or respiratory distress.

  • Infection Risk: Patients should be screened for Hepatitis B before starting therapy, as reactivation can occur.

  • Blood Counts: Regular monitoring of white blood cell and platelet counts is essential.

Why Source Enfiera from Ernest Oncology?

• Authentic Indian Exporter: Direct access to genuine Biochem Pharmaceutical inventory, providing 100% product authenticity and competitive wholesale pricing.

• Cold-Chain Authority: We utilize validated thermal shipping solutions to ensure Enfiera remains within the required temperature range during transit to the USA, UK, Australia, and South Africa.

• Regulatory Compliance: We provide all essential B2B documentation, including GMP compliance, batch-specific COAs, and necessary export permits.

• Bulk Supply Stability: We specialize in fulfilling large-scale orders for hospital groups, hematology centers, and regional distributors.